Jan. 26, 2026 -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic therapies, today announced the execution of a licensing agreement for 10XB-101, its investigational product for focal fat reduction and body contouring, along with a strategic equity investment by BNC Korea (KOSDAQ:256840), a leading healthcare and aesthetics-focused company in South Korea. “We are delighted to enter this strategic partnership with BNC Korea for 10XB-101, marking a signi

Jan. 26, 2026 -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio's

Genezen, a gene therapy contract development and manufacturing organization (CDMO) headquartered in Indianapolis, and Atsena Therapeutics, a clinical-stage gene therapy company based in Durham, North Carolina, announced a manufacturing partnership to support the clinical development and potential commercialization of Atsena’s adeno-associated virus gene therapy programs. Under the agreement, Genezen will provide viral vector manufacturing services to support Atsena’s existing AAV platform for b

Jan. 23, 2026 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the f

Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products. “The goal of this collaboration is to transform the way Rare and Orphan therapies are introduced to market, ensuring they reach the patients who need them most.” -Patrick Dunham, CEO and Co-Founder of Curant Health Rare di

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031. The acquisition gives AstraZeneca full global control over the development, manufacturing, and commercialisation of the therapy. AbelZeta will receive up to $630m from AstraZeneca, including upfront payments and milestone fees for the GPC3 programme in China. AstraZeneca previously held rights to C-CAR031 outside of China. AbelZeta remains eligible for additional milesto

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and potential commercialisation of its botensilimab and balstilimab (BOT/BAL) immunotherapy combination programme. The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus has provided Zydus with exclusive rights to d

NeuraLight, the leader in developing precision brain function measures, and Teitur Trophics ApS, a pioneering biotech company developing first-in-class therapeutics for neurodegenerative diseases, today announced that they have entered into a collaboration granting Teitur Trophics access to NeuraLight’s brain function biomarker platform for use in its upcoming clinical trial of TT-P34 in Parkinson’s disease. NeuraLight’s platform provides precise, actionable measures of brain function. The plat

Jan. 20, 2026 -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical tri

Jan. 15, 2026 -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently r